Trials / Not Yet Recruiting
Not Yet RecruitingNCT07319897
A Prospective, Multicenter, Diagnostic Study Evaluating 68Ga-BCMA PET/CT for Targeting BCMA Expression in Multiple Myeloma.
- Status
- Not Yet Recruiting
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- Sponsor
- Peking University First Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
This is a prospective, multicenter, diagnostic imaging study designed to evaluate the diagnostic performance and clinical utility of BCMA-targeted Positron Emission Tomography/Computed Tomography (PET/CT) in patients with multiple myeloma and other palsma cell disorders. The study aims to non-invasively visualize and quantify the whole-body biodistribution of BCMA expression.
Conditions
- Multiple Myeloma
- Multiple Myeloma and Malignant Plasma Cell Neoplasms
- Multiple Myeloma and Plasma Cell Neoplasm
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | 68Ga-BCMA PET/CT | Intravenous administration of the investigational BCMA-targeted radiopharmaceutical, followed by a whole-body PET/CT scan performed per a standardized protocol. |
Timeline
- Start date
- 2025-12-25
- Primary completion
- 2027-12-30
- Completion
- 2027-12-30
- First posted
- 2026-01-06
- Last updated
- 2026-01-06
Locations
5 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07319897. Inclusion in this directory is not an endorsement.